> Shares in Cassiopea jumped 76% on the back of phase 3 acne data. Hitting all three co-primary endpoints sets the Swiss biotech up to file for approval of the key pipeline prospect next year. Release
> The French state bank has teamed with Sanofi to create a €100 million ($117 million) biotech fund. Sanofi will contribute €50 million to the fund, which could swell to in size to €250 million if other investors get involved. Reuters
> Transgene secured a deal that will give it a €48 million stake in China’s Tasly Biopharmaceuticals. Statement
> TxCell licensed a HLA-A2 CAR-Treg program from the University of British Columbia. The chronic transplant rejection program is expected to move into phase 1 next year. Release
> ReNeuron received $2.5 million from an unidentified U.S. company as a precursor to a possible deal for its retinal stem cell technology and therapeutic programs. Statement